Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2025

Genmab — Marts 2025

Planlagt Fastgjort Låst Flyttet Genmab
961 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #863

    Almost like, maybe we stole your idea, but you never secured it through patent.

    1 Reply Last reply
    0
    • L Offline
      L Offline
      lahn1
      wrote on sidst redigeret af
      #864

      Jeg havde helst set at de argumenterede at de selv var kommet op med ideen frem for dette.

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #865

        yes Helge, it will always be difficult to judge a relationship from the outside, we'll probably never really know what exactly is at play. https://pharmaphorum.com/news/abbvie-sues-genmab-claiming-trade-secrets-theft

        1 Reply Last reply
        0
        • B Offline
          B Offline
          BioShare
          wrote on sidst redigeret af
          #866

          Helt enig lahn1, virker ikke gennemtænkt

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #867

            I think it is safe to assume they carefully worded their reply lahn , assume it was drafted by lawyers... if it is not something that needs protection (in a business where everything needs protecting) than maybe you don't think it is
            very valuable...

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #868

              I also had to think about the remark from Jan at the time of the AbbVie deal, when he spoke about 'AbbVie's next generation ADC technology'. So I assume at that time they studied AbbVie's technology, but were not impressed enough for it to lead to anything. (and why did Genmab only notice that special part of the ADC technology when Profound showed it, and not AbbVie?? Was it even shown?)

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #869

                Remember from that deal 'The discovery research collaboration will combine proprietary antibodies from both companies along with Genmab's DuoBody technology and AbbVie's payload and ADC technology to select and develop up to four additional differentiated next-generation antibody-based product candidates'.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #870

                  It had already been a question mark for me why there were was nothing coming out of this. I had assumed the 50/50 split could be a potential hurdle for AbbVie to develop with Genmab what they could potentially do cheaper with a royalty deal or themselves. But it doesn't immediately show a deep and strong partner relationship if nothing comes out of it.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #871

                    At the same time, these are 2 professional parties that should be able to put revenues first and therefore I am not that worried about Epcoritamab, not for current indications, nor for potential future plans for autoimmune diseases. But for now I am assuming the other part of the original deal is dead for now (I already sort of was assuming that...). Just like I don't expect any partnerships with JNJ anymore.

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gentogen
                      wrote on sidst redigeret af
                      #872

                      Regarding 12:24 the problem is that the wording is a wrong interpretation of what Genmab is saying. According to Genmab there was no trade secret in the first place (they call it an alleged trade secret several times) so they are not assuming that Abbvie had any innovation at all

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #873

                        Genmab trækkes ind i retssag om tyveri af forretningshemmelighed af amerikansk gigant https://proinvestor.com/investornyt/1295173/genmab-traekkes-ind-i-retssag-om-tyveri-af-forretningshemmelighed-af-amerikansk-gigant

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #874

                          Jyske Bank: Genmab – Sagsøgt af partneren AbbVie https://proinvestor.com/investornyt/1295153/jyske-bank-genmab-sagsogt-af-partneren-abbvie

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #875

                            On a separate note, I feal somewhat sorry for Jan, who, with a strong academic background where science and ideas are shared in a joint effort to bring technology forward, created a company with much of that idealisme as corner stone.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #876

                              From inception he encouraged openness of data and technology, looked for partnerships in academia, healthcare field and with competing pharma / bio. A strategy that backfired to him maybe just a few times to often. I wonder how his worldview has changed the last few years...

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #877

                                The world are moving in another direction now. But I admire his approach !

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  lahn1
                                  wrote on sidst redigeret af
                                  #878

                                  Gentogen, der er jeg da enig med.

                                  1 Reply Last reply
                                  0
                                  • L Offline
                                    L Offline
                                    lahn1
                                    wrote on sidst redigeret af
                                    #879

                                    EL 12:54, lets hope that. It will just make the case muck easier if Gmab has strong proof of independent development of the linker... case close sort of. But that might not be the case. and that make the protections around the alleged secret very importent. If there is no protection of the secret it is not a secret.

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      lahn1
                                      wrote on sidst redigeret af
                                      #880

                                      It might help our case if Genmab can show that Abbvie did not in 2020 in connection with their agreement nor later in their collaboration discussed this linker technology with Genmab.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #881

                                        AACR25 3424 / 19 - DuoBody®-FAPαxDR4 induces tumor cell death through FAPα-dependent, DR4 transactivation-mediated apoptosis https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/8381

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #882

                                          AACR25 5788 / 15 - Molecular profiling of NSCLC patients associates CT-based radiomic features with a tumor microenvironment favorable for immunotherapy https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/1563

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper